{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:59:38Z","timestamp":1787637578489,"version":"build-2736575974"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Anti-amyloid antibodies have the potential to become the standard of care in Alzheimer\u2019s Disease (AD) and large datasets from clinical trials allow the testing of predictive models on fluid biomarkers and functional outcomes. However, identifying an easily accessible biomarker to determine the time to switch to maintenance therapy, and identifying patient profiles with optimal cognitive benefit, are still unresolved issues in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Predicted changes in monomers, oligomers, protofibrils and plaques were simulated using a well-validated Quantitative Systems Pharmacology model based on biophysical and biological assumptions of amyloid synthesis, aggregation and clearance. This model was combined with a previously calibrated computational neuronal network model of cognitive outcome in AD patients by introducing the effect of amyloid and tau oligomers on specific voltage- and ligand-gated ion channels, informed by preclinical studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The model accounted for 70% and 50% of the variance of clinically observed changes in plasma p-tau181 and Clinical Dementia Rating-Sum Of Boxes (CDR-SOB) respectively, in clinical trials of seven amyloid antibodies. We derived an antibody specific normalized decrease of plasma p-tau181 (\u221215% for donanemab, \u221245% for aducanumab and \u221275% for lecanemab) to determine trial duration for achieving central amyloid negativity. Using the concept of information processing bandwidth, the model suggests that anti-amyloid antibodies slow the cognitive worsening compared to placebo while at the same time lowering plasma p-tau181 levels by reducing neuronal firing. Finally, the model suggests that independently from the degree of amyloid reduction, the beneficial cognitive effect of treatment decreases with more advanced neuronal pathology and higher baseline tau-load. This provides a hypothesis for the impact of disease pathology and gender effect on functional outcomes with lecanemab and gantenerumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>With further validation, this model has the capability to support optimization of clinical trial design for amyloid-tau combination therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1813290","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:44:30Z","timestamp":1777535070000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome. Insights from a comprehensive mechanistic quantitative systems pharmacology study"],"prefix":"10.3389","volume":"17","author":[{"given":"Hugo","family":"Geerts","sequence":"first","affiliation":[{"name":"Certara Predictive Technologies, Applied Biosimulation","place":["Radnor, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaina M.","family":"Short","sequence":"additional","affiliation":[{"name":"Certara Predictive Technologies, Applied Biosimulation","place":["Radnor, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena","family":"Grant","sequence":"additional","affiliation":[{"name":"Certara Predictive Technologies, Applied Biosimulation","place":["Radnor, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet H.","family":"van der Graaf","sequence":"additional","affiliation":[{"name":"Certara Predictive Technologies, Applied Biosimulation","place":["Radnor, PA, United States"]},{"name":"Leiden Academic Centre for Drug Research","place":["Leiden, Netherlands"]},{"name":"Cincinnati Children\u2019s Hospital Medical Center","place":["Cincinnati, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.3390\/ijms23084307","article-title":"Mechanisms involved in epileptogenesis in alzheimer\u2019s disease and their therapeutic implications","volume":"23","author":"Altuna","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e14467","DOI":"10.1002\/alz.14467","article-title":"The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect","volume":"21","author":"Andrews","year":"2025","journal-title":"Alzheimer\u2019s Dementia J. Alzheimer\u2019s Assoc."},{"key":"B3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.neuron.2012.03.023","article-title":"Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment","volume":"74","author":"Bakker","year":"2012","journal-title":"Neuron"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e775","DOI":"10.1212\/WNL.0000000000200667","article-title":"Novelty-Related fMRI responses of precuneus and medial temporal regions in individuals at risk for Alzheimer disease","volume":"99","author":"Billette","year":"2022","journal-title":"Neurology"},{"key":"B88","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ajpath.2015.09.018","article-title":"Synaptic amyloid-beta oligomers precede p-tau and differentiate high pathology control cases","volume":"186","author":"Bilousova","year":"2016","journal-title":"Am. J. Pathol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e082907","DOI":"10.1002\/alz.082907","article-title":"A\u00df oligomers peak in early clinical stages of Alzheimer\u00b4s disease and proceed Tau pathology","volume":"19","author":"Bl\u00f6meke","year":"2023","journal-title":"Alzheimer\u2019s Dementia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s10928-021-09776-7","article-title":"Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases","volume":"48","author":"Bloomingdale","year":"2021","journal-title":"J. Pharmacokinet. Pharmacodynamics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1016\/j.cell.2023.09.023","article-title":"Accelerating Alzheimer\u2019s therapeutic development: the past and future of clinical trials","volume":"186","author":"Boxer","year":"2023","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/brain\/awz060","article-title":"Tau suppresses neuronal activity in vivo, even before tangles form","volume":"142","author":"Busche","year":"2019","journal-title":"Brain"},{"key":"B10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41593-018-0289-8","article-title":"Tau impairs neural circuits, dominating amyloid-\u03b2 effects, in Alzheimer models in vivo","volume":"22","author":"Busche","year":"2019","journal-title":"Nat. Neurosci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2217\/fnl.11.50","article-title":"Early molecular and synaptic dysfunctions in the prodromal stages of Alzheimer\u2019s disease: focus on TNF-\u03b1 and IL-1I","volume":"6","author":"Cavanagh","year":"2011","journal-title":"Future Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"6739","DOI":"10.1007\/s00415-024-12631-7","article-title":"Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer\u2019s disease: a real-world study","volume":"271","author":"Cecchetti","year":"2024","journal-title":"J. Neurology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e26529","DOI":"10.1002\/hbm.26529","article-title":"Structural, static, and dynamic functional MRI predictors for conversion from mild cognitive impairment to Alzheimer\u2019s disease: Inter-cohort validation of Shanghai Memory Study and ADNI","volume":"45","author":"Chen","year":"2024","journal-title":"Hum. Brain Mapp."},{"key":"B14","volume-title":"Lecanemab clarity AD: results from a randomised, double-blind phase 3 early Alzheimer\u2019s disease trial","author":"Christopher","year":"2023"},{"key":"B15","doi-asserted-by":"publisher","first-page":"102643","DOI":"10.1016\/j.nicl.2021.102643","article-title":"Latent patterns of task-related functional connectivity in relation to regions of hyperactivation in individuals at risk of Alzheimer\u2019s disease","volume":"30","author":"Corriveau-Lecavalier","year":"2021","journal-title":"NeuroImage Clin."},{"key":"B87","doi-asserted-by":"crossref","first-page":"e2671","DOI":"10.1038\/cddis.2017.97","article-title":"Membrane association and release of wild-type and pathological tau from organotypic brain slice cultures","volume":"8","author":"Croft","year":"2017","journal-title":"Cell Death Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1111\/cogs.12613","article-title":"Generalized information theory meets human cognition: introducing a unified framework to model uncertainty and information search","volume":"42","author":"Crupi","year":"2018","journal-title":"Cognitive Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ana.26817","article-title":"Proteomic indicators of health predict Alzheimer\u2019s disease biomarker levels and dementia risk","volume":"95","author":"Dark","year":"2024","journal-title":"Ann. Neurology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"103250","DOI":"10.1016\/j.jbi.2019.103250","article-title":"Physiological synchronization and entropy as measures of team cognitive load","volume":"96","author":"Dias","year":"2019","journal-title":"J. Biomed. Inf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.3390\/cells11101650","article-title":"Concomitant retinal alterations in neuronal activity and TNF\u03b1 pathway are detectable during the pre-symptomatic stage in a mouse model of Alzheimer\u2019s disease","volume":"11","author":"Dinet","year":"2022","journal-title":"Cells"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/mp.2014.9","article-title":"Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study","volume":"19","author":"Doraiswamy","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3233\/JAD-220857","article-title":"Associations between hyperactive neuropsychiatric symptoms and brain morphology in mild cognitive impairment and Alzheimer\u2019s disease","volume":"97","author":"El Haffaf","year":"2024","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e13455","DOI":"10.1111\/acel.13455","article-title":"Synaptic dysregulation and hyperexcitability induced by intracellular amyloid beta oligomers","volume":"20","author":"Fernandez-Perez","year":"2021","journal-title":"Aging Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00234-024-03323-0","article-title":"Arterial spin labelling magnetic resonance imaging and perfusion patterns in neurocognitive and other mental disorders: a systematic review","volume":"66","author":"Ferreira","year":"2024","journal-title":"Neuroradiology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e70086","DOI":"10.1002\/alz.70086","article-title":"Lecanemab preferentially binds to smaller aggregates present at early Alzheimer\u2019s disease","volume":"21","author":"Fertan","year":"2025","journal-title":"J. Alzheimer\u2019s Assoc."},{"key":"B25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10877-023-01051-z","article-title":"An in-depth analysis of parameter settings and probability distributions of specific ordinal patterns in the Shannon permutation entropy during different states of consciousness in humans","volume":"38","author":"Franka","year":"2023","journal-title":"J. Clin. Monit. Comput."},{"key":"B26","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/alz.12082","article-title":"Learning from amyloid trials in Alzheimer\u2019s disease. A virtual patient analysis using a quantitative systems pharmacology approach","volume":"16","author":"Geerts","year":"","journal-title":"Alzheimer\u2019s Dementia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3233\/JAD-200688","article-title":"Simulating the effects of common comedications and genotypes on alzheimer\u2019s cognitive trajectory using a quantitative systems pharmacology approach","volume":"78","author":"Geerts","year":"","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1038\/psp.2013.12","article-title":"A quantitative system pharmacology computer model for cognitive deficits in schizophrenia","volume":"2","author":"Geerts","year":"2013","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-018-0343-5","article-title":"Impact of amyloid-beta changes on cognitive outcomes in Alzheimer\u2019s disease: analysis of clinical trials using a quantitative systems pharmacology model","volume":"10","author":"Geerts","year":"2018","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e082487","DOI":"10.1002\/alz.082487","article-title":"Exploring treatment guidelines for amyloid therapies in Alzheimer\u2019s Disease using predictive quantitative system pharmacology modeling","volume":"19","author":"Geerts","year":"","journal-title":"Alzheimer\u2019s Dementia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/psp4.12912","article-title":"A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer\u2019s disease","volume":"12","author":"Geerts","year":"","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1523\/JNEUROSCI.0876-20.2020","article-title":"Implications of oligomeric amyloid-beta (oA\u03b242) signaling through \u03b17\u03b22-nicotinic acetylcholine receptors (nAChRs) on basal forebrain cholinergic neuronal intrinsic excitability and cognitive decline","volume":"41","author":"George","year":"2021","journal-title":"J. Neurosci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/brain\/awz381","article-title":"Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy","volume":"143","author":"Gourmaud","year":"2020","journal-title":"Brain"},{"key":"B86","doi-asserted-by":"crossref","first-page":"824454","DOI":"10.3389\/fnins.2022.824454","article-title":"TNF-alpha orchestrates experience-dependent plasticity of excitatory and inhibitory synapses in the anterior piriform cortex","volume":"16","author":"Guo","year":"2022","journal-title":"Front Neurosci."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of amyloid and Tau with cognition in preclinical alzheimer disease: a longitudinal Study","volume":"76","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e70223","DOI":"10.1002\/psp4.70223","article-title":"Quantitative systems pharmacology models of anti-amyloid treatments for Alzheimer\u2019s disease: a systematic review","volume":"15","author":"Herriott","year":"2026","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0166-19.2019","article-title":"Introduction of Tau oligomers into cortical neurons alters action potential dynamics and disrupts synaptic transmission and plasticity","volume":"6","author":"Hill","year":"2019","journal-title":"ENeuro"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/s42003-021-02791-x","article-title":"Truncating tau reveals different pathophysiological actions of oligomers in single neurons","volume":"4","author":"Hill","year":"2021","journal-title":"Commun. Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/107385840100700207","article-title":"NEURON: a tool for neuroscientists","volume":"7","author":"Hines","year":"2001","journal-title":"Neurosci. A Rev. J. Bringing Neurobiol. Neurology Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1113\/jphysiol.1952.sp004764","article-title":"A quantitative description of membrane current and its application to conduction and excitation in nerve","volume":"117","author":"Hodgkin","year":"1952","journal-title":"J. Physiology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1523\/JNEUROSCI.1397-18.2018","article-title":"Tau accumulation in clinically normal older adults is associated with hippocampal hyperactivity","volume":"39","author":"Huijbers","year":"2019","journal-title":"J. Neurosci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/archneur.64.9.1312","article-title":"Superior frontal cortex cholinergic axon density in mild cognitive impairment and early Alzheimer disease","volume":"64","author":"Ikonomovic","year":"2007","journal-title":"Archives Neurology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.neucli.2020.05.001","article-title":"Electrophysiological differences in cortical excitability in different forms of dementia: a transcranial magnetic stimulation and laboratory biomarkers study","volume":"50","author":"Khedr","year":"","journal-title":"Neurophysiol. Clin."},{"key":"B43","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3233\/JAD-200885","article-title":"Cognitive impairment, P300, and transforming growth factor \u03b21 in different forms of dementia","volume":"78","author":"Khedr","year":"","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3233\/JAD-221001","article-title":"Investigating compensatory brain activity in older adults with subjective cognitive decline","volume":"93","author":"Krebs","year":"2023","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"B85","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40478-024-01758-3","article-title":"Neuropathological changes associated with aberrant cerebrospinal fluid p-tau181 and A\u03b242 in Alzheimer\u2019s disease and other neurodegenerative diseases","volume":"12","author":"Kurihara","year":"2024","journal-title":"Acta Neuropathol. Commun."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1016\/j.neurobiolaging.2015.07.009","article-title":"Disruption of cholinergic neurotransmission exacerbates A\u03b2-related cognitive impairment in preclinical Alzheimer\u2019s disease","volume":"36","author":"Lim","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"B46","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/psp4.12972","article-title":"QSP designer: quantitative systems pharmacology modeling with modular biological process map notation and multiple language code generation","volume":"12","author":"Matthews","year":"2023","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1002\/alz.12877","article-title":"Development of a quantitative semi-mechanistic model of Alzheimer\u2019s disease based on the amyloid\/tau\/neurodegeneration framework (the Q-ATN model)","volume":"19","author":"Mazer","year":"2023","journal-title":"J. Alzheimer\u2019s Assoc."},{"key":"B48","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1523\/JNEUROSCI.5215-08.2009","article-title":"Amyloid \u03b2-induced neuronal hyperexcitability triggers progressive epilepsy","volume":"29","author":"Minkeviciene","year":"2009","journal-title":"J. Neurosci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e0127264","DOI":"10.1371\/journal.pone.0127264","article-title":"Small-conductance Ca2+-activated potassium type 2 channels regulate the formation of contextual fear memory","volume":"10","author":"Murthy","year":"2015","journal-title":"PLoS One"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e75316","DOI":"10.7554\/eLife.75316","article-title":"Biophysical Kv3 channel alterations dampen excitability of cortical PV interneurons and contribute to network hyperexcitability in early Alzheimer\u2019s","volume":"11","author":"Olah","year":"2022","journal-title":"ELife"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1212\/WNL.0000000000006875","article-title":"Associations between tau, A\u03b2, and cortical thickness with cognition in Alzheimer disease","volume":"92","author":"Ossenkoppele","year":"2019","journal-title":"Neurology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/s41593-025-02000-6","article-title":"Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-\u03b2 status, APOE genotype and sex","volume":"28","author":"Ossenkoppele","year":"2025","journal-title":"Nat. Neurosci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e1005025","DOI":"10.1371\/journal.pgen.1005025","article-title":"Linking A\u03b242-Induced hyperexcitability to neurodegeneration, learning and motor deficits, and a shorter lifespan in an Alzheimer\u2019s model","volume":"11","author":"Ping","year":"2015","journal-title":"PLoS Genet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol."},{"key":"B83","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/alzrt214","article-title":"Propagation of tau pathology in Alzheimer\u2019s disease: identification of novel therapeutic targets","volume":"5","author":"Pooler","year":"2013","journal-title":"Alzheimers Res. Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neunet.2017.07.016","article-title":"Entropy factor for randomness quantification in neuronal data","volume":"95","author":"Rajdl","year":"2017","journal-title":"Neural Netw."},{"key":"B57","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41598-017-18729-5","article-title":"Amyloid \u03b2 causes excitation\/inhibition imbalance through dopamine receptor 1-dependent disruption of fast-spiking GABAergic input in anterior cingulate cortex","volume":"8","author":"Ren","year":"2018","journal-title":"Sci. Rep."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.57513","article-title":"Microglia TREM2R47H Alzheimer-linked variant enhances excitatory transmission and reduces LTP via increased TNF-\u03b1 levels","volume":"9","author":"Ren","year":"2020","journal-title":"ELife"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.016395","article-title":"TNF-\u03b1-mediated reduction in inhibitory neurotransmission precedes sporadic Alzheimer\u2019s disease pathology in young Trem2R47H rats","volume":"296","author":"Ren","year":"2021","journal-title":"J. Biol. Chem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1021\/acsmedchemlett.1c00048","article-title":"Discovery of investigational drug CT1812, an antagonist of the Sigma-2 receptor complex for alzheimer\u2019s disease","volume":"12","author":"Rishton","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"B61","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/alzrt153","article-title":"Simulations of symptomatic treatments for Alzheimer\u2019s disease: computational analysis of pathology and mechanisms of drug action","volume":"4","author":"Roberts","year":"2012","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neurobiolaging.2024.01.014","article-title":"The spatial distribution of coupling between tau and neurodegeneration in amyloid-\u03b2 positive mild cognitive impairment","volume":"136","author":"Robinson","year":"2024","journal-title":"Neurobiol. Aging"},{"key":"B63","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.bbi.2023.07.007","article-title":"Interleukin-10 enhances activity of ventral tegmental area dopamine neurons resulting in increased dopamine release","volume":"113","author":"Ronstr\u00f6m","year":"2023","journal-title":"Brain, Behav. Immun."},{"key":"B64","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JAD-220983","article-title":"Etiology and clinical significance of network hyperexcitability in Alzheimer\u2019s disease: unanswered questions and next steps","volume":"92","author":"Samudra","year":"2023","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"103625","DOI":"10.1016\/j.nicl.2024.103625","article-title":"BOLD signal variability as potential new biomarker of functional neurological disorders","volume":"43","author":"Schneider","year":"2024","journal-title":"NeuroImage. Clin."},{"key":"B66","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1523\/JNEUROSCI.4637-10.2011","article-title":"Information capacity and transmission are maximized in balanced cortical networks with neuronal avalanches","volume":"31","author":"Shew","year":"2011","journal-title":"J. Neurosci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"B68","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.neuron.2019.08.008","article-title":"Pathogenic tau impairs axon initial segment plasticity and excitability homeostasis","volume":"104","author":"Sohn","year":"2019","journal-title":"Neuron"},{"key":"B69","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.neuroscience.2018.01.066","article-title":"On information metrics for spatial coding","volume":"375","author":"Souza","year":"2018","journal-title":"Neuroscience"},{"key":"B70","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11481-024-10112-2","article-title":"Activation of the CXCR4 receptor by chemokine CXCL12 increases the excitability of neurons in the rat Central Amygdala","volume":"19","author":"Sowa","year":"2024","journal-title":"J. Neuroimmune Pharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1103\/PhysRevLett.80.197","article-title":"Entropy and information in neural spike trains","volume":"80","author":"Strong","year":"1998","journal-title":"Phys. Rev. Lett."},{"key":"B72","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/hipo.22403","article-title":"Intrinsic excitability changes induced by acute treatment of hippocampal CA1 pyramidal neurons with exogenous amyloid \u03b2 peptide","volume":"25","author":"Tamagnini","year":"2015","journal-title":"Hippocampus"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e258","DOI":"10.1212\/WNL.0000000000200351","article-title":"Brain metabolism and amyloid load in individuals with subjective cognitive decline or pre-mild cognitive impairment","volume":"99","author":"Tondo","year":"2022","journal-title":"Neurology"},{"key":"B75","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.cell.2021.12.041","article-title":"Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration","volume":"185","author":"Tracy","year":"2022","journal-title":"Cell"},{"key":"B84","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"e8643","DOI":"10.1371\/journal.pone.0008643","article-title":"A new target for amyloid beta toxicity validated by standard and high-throughput electrophysiology","volume":"5","author":"Varghese","year":"2010","journal-title":"PLoS One"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e8366","DOI":"10.1371\/journal.pone.0008366","article-title":"Opposite effects of low and high doses of A\u03b242 on electrical network and neuronal excitability in the rat prefrontal cortex","volume":"4","author":"Wang","year":"2009","journal-title":"PLoS One"},{"key":"B78","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3389\/fncel.2013.00129","article-title":"Multiple effects of \u03b2-amyloid on single excitatory synaptic connections in the PFC","volume":"7","author":"Wang","year":"2013","journal-title":"Front. Cell. Neurosci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-016-0143-y","article-title":"The release and trans-synaptic transmission of Tau via exosomes","volume":"12","author":"Wang","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"B80","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/psp4.13095","article-title":"Microglial roles in Alzheimer\u2019s disease: an agent-based model to elucidate microglial spatiotemporal response to beta-amyloid","volume":"13","author":"Weathered","year":"2024","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/nn.4328","article-title":"Neuronal activity enhances tau propagation and tau pathology in vivo","volume":"19","author":"Wu","year":"2016","journal-title":"Nat. Neurosci."},{"key":"B82","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1084\/jem.20131685","article-title":"Neuronal activity regulates extracellular tau in vivo","volume":"211","author":"Yamada","year":"2014","journal-title":"J. Exp. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1813290\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:44:32Z","timestamp":1777535072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1813290\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":88,"alternative-id":["10.3389\/fphar.2026.1813290"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1813290","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"1813290"}}